Your English writing platform
Discover LudwigExact(5)
Mark Dawson, E. M. S. et al. A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML).
Phase I open label observational trial, in the UK.
This phase I open label study was divided into two parts.
In a phase I, open label trial (n = 27), serum drug levels were measured on 3 occasions, 1 week apart.
This was a phase I, open label, single institution, 3 + 3 dose escalation study of oral HCQ with intravenous, weekly TEM in patients with advanced solid tumors.
Similar(55)
A phase I open-label study was undertaken to establish the tolerability profile and determine the recommended dose (RD) and administration schedule.
Drew Rasco, A. T. et al. Abstract CT038: A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma.
Moreno, V. et al. A phase I, open-label, study of GSK2879552, a lysine-specific demethylase 1 (LSD1) inhibitor, in patients with relapsed/refractory small cell lung carcinoma (SCLC).
The combination of anti-CTLA4 mAb and PF-3512676 is currently being evaluated in a phase I, open-label, nonrandomized, dose-escalation study in patients with metastatic melanoma and may provide a foundation for future therapeutic approaches.
A phase I open-label dose-escalation study was conducted to define the safety, tolerability, and pharmacokinetics (PK) of PankoMab-GEX, a glyco-optimised humanised IgG1, with high affinity to a novel tumour-specific glycopeptide epitope of MUC1 (TA-MUC1) with excellent preclinical anti-tumour activity.
AVXS-101-CL-303: Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN 2 CopiesPhase I, Open-Label, Dose Comparison Study of AVXS-101 by Intravenous Infusion (STRIVE) GENE TRANSFER.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com